(Anselamimab)Biosimilar Reference Antibody-GS40030

货号：GS40030

Anselamimab (also known as CAEL-101 or 11-1F4) is a chimeric monoclonal antibody (mAb) designed as a potential, first-in-class therapy for light chain-associated (AL) amyloidosis. AL amyloidosis is a rare, systemic, and progressive disorder caused by the abnormal misfolding and deposition of immunoglobulin light chain fragments into toxic amyloid fibrils. Anselamimab acts as an anti-fibril depleter antibody. Upon administration, it specifically targets a conformational epitope found on the LC-related amyloid fibrils that are deposited in organs like the heart and kidneys. By binding to these existing deposits, the antibody is thought to induce an Fc-mediated cellular inflammatory response (phagocytosis), promoting the degradation and elimination of the amyloid deposits, which current standard therapies do not directly address. While Phase III trials did not meet the primary endpoint in the overall population, data suggested a clinically meaningful benefit in a prespecified subgroup of patients.